

# TYSABRI (NATALIZUMAB) [PREFERRED] PRIOR AUTHORIZATION FORM



Keystone First

**PERFORMRx**<sup>SM</sup>  
Next Generation Pharmacy Benefits

(form effective 7/30/20)

Fax to PerformRx<sup>SM</sup> at **1-215-937-5018**, or to speak to a representative call **1-800-588-6767**.

## PRIOR AUTHORIZATION REQUEST INFORMATION

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request	Total # pages:	Name of office contact:
Contact's phone number:	LTC facility contact/phone:	

## PATIENT INFORMATION

Patient name:	Patient ID #:	DOB:
Street address:	Apt. #:	City/state/zip:

## PRESCRIBER INFORMATION

Prescriber name:	Specialty:	
State license #:	NPI:	MA Provider ID #
Street address:	Suite #:	City/state/zip:
Phone:	Fax:	

## CLINICAL INFORMATION

Medication requested: Tysabri (natalizumab) 300 mg/15 ml	Quantity:                      vials	Refills:
Directions: <input type="checkbox"/> 300 mg SQ every 4 weeks <input type="checkbox"/> other: _____	Dx code ( <i>required</i> ):	
Diagnosis: <input type="checkbox"/> relapsing multiple sclerosis – <i>Submit documentation of diagnosis and disease pattern.</i> <input type="checkbox"/> moderately to severely active Crohn's disease with inflammation – <i>Submit documentation of diagnosis and disease severity.</i> <input type="checkbox"/> other: _____ – <i>Submit documentation supporting the use of Tysabri for the patient's condition.</i>		

## PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication, if applicable):

Deliver to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Preferred Pharmacy Name:	
Pharmacy Phone #:	Pharmacy Fax #:
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.	

## HCPCS (HEALTHCARE COMMON PROCEDURE CODING SYSTEM) INFORMATION (if applicable):

Treatment setting: <input type="checkbox"/> Infusion Center <input type="checkbox"/> Home <input type="checkbox"/> Provider's Office <input type="checkbox"/> Hospital Outpatient Facility		
Facility name:	Facility NPI:	
J-code:	Number of units:	Date of service (MM/DD/YYYY):

## INITIAL REQUESTS

1. Does the patient have results of baseline testing for anti-JC virus antibodies? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>
2. <b>For the treatment of MS</b> , did the patient have a baseline MRI scan of the brain prior to initiating Tysabri? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>
3. <b>For the treatment of Crohn's disease</b> , does the patient have a history of a 3-month trial and failure of, or contraindication or intolerance to, the following medications? Check all that apply. <input type="checkbox"/> aminosalicylates (e.g., mesalamine, sulfasalazine) <input type="checkbox"/> immune modulators (e.g., azathioprine, methotrexate, 6-mercaptopurine) <input type="checkbox"/> TNF-a inhibitors (e.g., Humira) <input type="checkbox"/> Yes – List medications being used: <input type="checkbox"/> No

## RATIONALE FOR HOSPITAL OUTPATIENT FACILITY TREATMENT SETTING (if applicable):

<input type="checkbox"/> Documented history of severe adverse reaction occurred during or immediately following an infusion and/or the adverse reaction did not respond to conventional interventions
<input type="checkbox"/> Documentation that the member is medically unstable for the safe and effective administration of the prescribed medication at an alternative site of care as a result of one of the following: <input type="checkbox"/> Complex medical condition, status, or therapy requires services beyond the capabilities of an office or home infusion setting (clinical instability or a complex regimen that requires frequent clinical assessment or monitoring, which would be beyond the capabilities of an office or home infusion setting) <input type="checkbox"/> Documented history of medical instability, significant comorbidity, or concerns regarding fluid status inhibits treatment at a less intensive site of care (unstable fluid status associated with heart failure or advanced [stage 4 or 5] renal failure)

## RENEWAL REQUESTS

1. Did the patient experience disease improvement or stabilization since starting Tysabri? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation of response to therapy.</i>
2. <b>If baseline testing for anti-JC virus antibodies was negative</b> , does the patient have results of repeat testing since starting Tysabri? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>
3. <b>For the treatment of Crohn's disease</b> , was the patient able to discontinue use of steroid medications within 6 months of starting Tysabri? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>
4. <b>For the treatment of Crohn's disease</b> , did the patient require steroids to control symptoms for more than 3 months in the past year? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>

## PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:	Date:
-----------------------	-------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.